Skip to main content
. Author manuscript; available in PMC: 2017 Feb 3.
Published in final edited form as: Oncogene. 2016 Feb 15;35(36):4798–4806. doi: 10.1038/onc.2016.12

Figure 4.

Figure 4

Greater instability of p53 in 2780CP/Cl-16 cells is not associated with cisplatin resistance. (A) A2780, 2780CP/Cl-16 and 2780CP/Cl-24 cells were exposed at 37°C to increasing concentrations of cisplatin, and cells harvested 48 hours later for assessment of inactive pro-caspase-3 and active cleaved caspase-3 by Western blot. (B) A2780, 2780CP/Cl-16 and 2780CP/Cl-24 cells, with the indicated p53 status, were transfected at 37°C with MDM2 or MDM4 siRNA as described in Figure 3, and p53 and p21 were examined by Western blot. (C) Tumor cells grown at 37°C were exposed to vehicle or 1 μM (A2780) or 2 μM (2780CP/Cl-16 and 2780CP/Cl-24) cisplatin for 24 hours, and then collected for Western blot analysis using the indicated antibodies. The immunoblots for p21 were developed using either a short or long exposure condition.